Form 4: STAAR Surgical Director Receives Annual Equity Compensation Awards

STAAR Surgical Co. Director Elizabeth Yeu was granted 5,341 Restricted Stock Units and 9,708 Common Stock Options on June 18, 2025, as part of the company's routine non-employee director equity compensation program.

Summary

• Elizabeth Yeu, a Director of STAAR Surgical Co. (STAA), received equity awards on June 18, 2025.
• The awards consist of 5,341 Restricted Stock Units (RSUs) and 9,708 Common Stock Options.
• These awards are part of the Corporation's annual non-employee director equity compensation program for the 2025-2026 term.
• Each Restricted Stock Unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting.
• The Common Stock Options have an exercise price of $16.85 and an expiration date of June 17, 2035.
• Both the RSUs and Common Stock Options are scheduled to vest in full on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders.

Sentiment

Score: 7

Explanation: The document reports a routine and expected equity compensation grant to a director, which is a positive for aligning interests but does not contain significant new financial or operational news to dramatically shift sentiment.

Positives

• The grant of equity awards aligns the interests of the director with those of shareholders, as the awards vest over time and are tied to the company's performance.
• The compensation program helps attract and retain qualified non-employee directors, contributing to stable corporate governance.

Future Outlook

The document indicates future vesting events for the equity awards, specifically on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders.

Management Comments

• The equity awards were granted "pursuant to the Corporation's annual non-employee director equity compensation program for the 2025-2026 term."

Industry Context

This Form 4 filing reports a routine insider transaction related to director compensation. The practice of granting equity awards to non-employee directors is a standard corporate governance practice across various industries, including the medical device sector, to align director interests with those of shareholders and to attract and retain qualified board members.

Comparison to Industry Standards

• The granting of equity awards, specifically Restricted Stock Units and stock options, to non-employee directors is a widely accepted and standard compensation practice within publicly traded companies, including those in the medical technology and device industry like STAAR Surgical.
• While specific compensation amounts vary based on company size, performance, and peer group benchmarking, the structure of providing equity as a component of director remuneration is consistent with global benchmarks for corporate governance and executive compensation.

Corporate Governance

Related Party Transactions

• The equity award grant to Director Elizabeth Yeu is a related party transaction, representing compensation provided by the company to a member of its board of directors as part of its established compensation program.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is mentioned in this filing.

Next Steps

• Vesting of Restricted Stock Units and Common Stock Options on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders.

Key Dates

Keywords

STAAR Surgical, STAA, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Elizabeth Yeu